close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

728.41 -6.79 (-0.92%)
Delayed Quote Updated: 3:36 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
Why Regeneron (REGN) Stock Is Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all... 
Via StockStory
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,... 
Via MarketBeat
Topics ETFs
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount ↗
Via Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat ↗
Via Chartmill
News headline image
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗
The healthcare company will release its third-quarter results next month. 
Via The Motley Fool
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development... 
Via MarketBeat
Topics ETFs
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global... 
Via MarketBeat
Topics Intellectual Property
News headline image
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo... 
Via MarketBeat
Topics ETFs
News headline image
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p... 
Via StockStory
Topics Stocks
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron... 
Via Benzinga
News headline image
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron... 
Via Benzinga
News headline image
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool
News headline image
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
They are way more than just GLP-1 stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron... 
Via Benzinga
News headline image
The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call
Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s e... 
Via StockStory
Topics Earnings
News headline image
1 Value Stock with Promising Prospects and 2 We Avoid
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗
Revenue surged 17% as Dupixent and EYLEA HD posted record sales. 
Via The Motley Fool
Topics Earnings
News headline image
REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion.... 
Via StockStory
News headline image
Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗
Revenue surged 17% as Dupixent and EYLEA HD posted record sales. 
Via The Motley Fool
Topics Earnings
News headline image
Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales
Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billi... 
Via StockStory
Topics Artificial Intelligence
News headline image
Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know. Regeneron beat analysts’ reven... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.